Dermapharm Holding (XTRA:DMP) Posted Stronger Half Year Results, Does The Valuation Still Look Cheap?

Dermapharm Holding (XTRA:DMP) attracted fresh attention after its second quarter and half year 2026 earnings, with sales and net income figures that gave investors new data points to reassess the stock.

The latest earnings arrive after a mixed year for Dermapharm Holding’s stock, with the share price up 1.04% year to date but down 18.09% over three months and 5.92% over the past month. At the same time, the 1 year total shareholder return of 20.25% suggests that momentum has cooled recently rather than completely faded.

Position your portfolio alongside Dermapharm Holding's latest earnings momentum by reviewing our hand picked 271 high quality undervalued stocks that also combine growing sales with solid balance sheets.

Bullish investors point to Dermapharm Holding’s growing earnings, while bears highlight the weak recent share price. The next step is to see which side the current valuation appears to support.

Price-to-Earnings of 13.2x: Is it justified?

Dermapharm Holding is currently described as good value on a P/E of 13.2x, while trading at €38.95 as of the latest close. That contrasts with much higher P/E levels cited for both its peer group and the wider European pharmaceuticals sector.

The P/E ratio compares Dermapharm Holding's share price with its earnings per share and is a common yardstick in pharmaceuticals where steady profitability is important. A lower P/E relative to peers can signal that the market is assigning a more cautious earnings outlook or is slower to re-rate after a period of improved profitability.

In Dermapharm Holding's case, the statements indicate that the stock is on a P/E of 13.2x compared with an estimated fair P/E of 21.2x. That fair ratio level represents where the valuation could trend if the market price moved closer to the level implied by the relationship between fundamentals and valuation used in the model.

The same data also reports that Dermapharm Holding's 13.2x P/E is below both the European pharmaceuticals industry average of 21.5x and a peer average of 23x. This is strong comparative language for investors who pay attention to relative valuation because it suggests the current market pricing is materially lower than both sector and peer benchmarks, while the fair ratio points to additional room for re rating if sentiment shifts.

Explore the SWS fair ratio for Dermapharm Holding

Result: Price-to-Earnings of 13.2x (UNDERVALUED)

However, Dermapharm Holding still faces risks if revenue growth of 3.97% and net income growth of 7.61% weaken, or if its parallel import segment comes under pricing pressure.

Find out about the key risks to this Dermapharm Holding narrative.

Another view on Dermapharm Holding's value

The P/E screening paints Dermapharm Holding as good value. A second check using our DCF model is even more aggressive. It suggests a future cash flow value of €99.23 per share compared with the current €38.95 price, which flags the stock as heavily undervalued. The question is whether you trust the earnings based shortcut or the longer term cash flow view more.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Dermapharm Holding for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 271 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given this mix of cautious and optimistic signals around Dermapharm Holding, it makes sense to review the detailed risk and reward data yourself and move quickly if you want to shape your own view. To see both sides set out clearly, start with these 5 key rewards and 2 important warning signs

Looking for more investment ideas beyond Dermapharm Holding?

If Dermapharm Holding has your attention, do not stop there. Broaden your opportunity set and compare it with other stocks that match different strengths and profiles.

• Target income potential by reviewing companies in our 412 dividend fortresses that could complement Dermapharm Holding in an income focused portfolio.
• Consider your downside protection by scanning resilient businesses in the 303 resilient stocks with low risk scores and assessing how their stability fits your overall strategy.
• Explore our 621 high quality undiscovered gems to see which under-the-radar stocks might deserve a closer look alongside Dermapharm Holding.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com